Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 187

Similar articles for PubMed (Select 19718796)

1.

Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.

Zou P, Xu S, Povoski SP, Wang A, Johnson MA, Martin EW Jr, Subramaniam V, Xu R, Sun D.

Mol Pharm. 2009 Mar-Apr;6(2):428-40. doi: 10.1021/mp9000052.

2.

124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.

Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mojzisik CM, Johnson MA, Knopp MV, Martin EW Jr, Sun D.

World J Surg Oncol. 2010 Aug 6;8:65. doi: 10.1186/1477-7819-8-65.

3.

Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.

Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ.

Clin Cancer Res. 1999 Oct;5(10 Suppl):2994s-3000s.

PMID:
10541333
4.
5.

Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.

Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G.

Cancer Biother Radiopharm. 2006 Apr;21(2):106-16.

PMID:
16706631
6.

Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49.

Tang Y, Yang S, Gariépy J, Scollard DA, Reilly RM.

Bioconjug Chem. 2007 May-Jun;18(3):677-84. Epub 2007 Mar 16.

PMID:
17361988
7.

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.

Cancer Biother Radiopharm. 2005 Oct;20(5):502-13. Erratum in: Cancer Biother Radiopharm. 2005 Dec;20(6):671.

PMID:
16248766
8.

Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.

Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D.

J Nucl Med. 1999 Sep;40(9):1536-46.

9.

Targeting strategies for cancer radiotherapy.

Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3048s-3055s.

PMID:
10541342
10.

Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model.

Yu Y, Fang L, Sun D.

Int J Pharm. 2010 Feb 15;386(1-2):208-15. doi: 10.1016/j.ijpharm.2009.11.020. Epub 2009 Nov 26.

11.

Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.

Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3153s-3159s.

PMID:
10541357
12.

Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.

Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW.

Cancer. 2010 Feb 15;116(4 Suppl):1059-66. doi: 10.1002/cncr.24793.

13.

A CDR-grafted (humanized) domain-deleted antitumor antibody.

Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH.

Cancer Biother Radiopharm. 1997 Oct;12(5):305-16.

PMID:
10851481
14.

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH.

Hybridoma. 1995 Oct;14(5):461-73.

PMID:
8575795
15.

Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.

Roberson PL, Yokoyama S, Rogers BE, Buchsbaum DJ.

Cancer Biother Radiopharm. 2003 Apr;18(2):239-47.

PMID:
12804050
16.

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2005 Nov 15;11(22):8180-5.

17.

Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.

Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL.

Clin Cancer Res. 1997 Sep;3(9):1547-55.

18.

111In-(1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaaetic acid)-anti–TAG-72 humanized CH2 domain-deleted antibody .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Aug 17 [updated 2008 Feb 12].

19.

Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice.

Cheng Z, Levi J, Xiong Z, Gheysens O, Keren S, Chen X, Gambhir SS.

Bioconjug Chem. 2006 May-Jun;17(3):662-9.

20.

Radioiodinated anti-TAG-72 humanized CH2 domain-deleted antibody .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Aug 30 [updated 2007 Nov 14].

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk